Candid Therapeutics, Inc.
Candid Therapeutics, Inc., a pioneering biopharmaceutical company headquartered in the United States, is dedicated to advancing innovative therapies for patients with unmet medical needs. Founded in 2018, Candid Therapeutics focuses on developing cutting-edge treatments in the fields of neurology and rare diseases, leveraging its expertise in drug discovery and development. The company’s core offerings include a unique portfolio of therapeutic candidates designed to address complex neurological disorders. Candid Therapeutics distinguishes itself through its commitment to precision medicine and patient-centric approaches, aiming to improve outcomes for individuals suffering from debilitating conditions. With a strong market position and a growing reputation for excellence, Candid Therapeutics continues to make significant strides in the biopharmaceutical industry, contributing to the advancement of healthcare solutions.
DitchCarbon Score
How does Candid Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Candid Therapeutics, Inc.'s score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Candid Therapeutics, Inc.'s reported carbon emissions
Candid Therapeutics, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and formal commitments suggests that Candid Therapeutics may still be in the early stages of developing a comprehensive climate strategy. As the company operates within the biopharmaceutical sector, it is essential for Candid Therapeutics to consider establishing measurable climate commitments and reduction targets in line with industry standards. This could include aligning with frameworks such as the Science Based Targets initiative (SBTi) to enhance their sustainability profile and contribute to broader climate goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Candid Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
